Advances in binder identification and characterisation: The case of oligonucleotide aptamers

New Biotechnology

Volumn 29, Issue 5, 2012, Pages 550-554

  Taouji, Saïd ^a,b   Dausse, Eric ^a,c   Evadé, Laetitia ^a,c   Di Primo, Carmelo ^a,c   Toulmé, Jean Jacques ^a,c   Chevet, Eric ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Bordeaux Institute of Oncology   (France)

^c INSERM U869   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMERS; SYNTHETIC PROTEIN;

OLIGONUCLEOTIDES;

BINDERS;

APTAMER; SINGLE STRANDED DNA;

ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); DNA LIBRARY; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HIGH THROUGHPUT SEQUENCING; IN VITRO STUDY; LIMIT OF DETECTION; MASS SPECTROMETRY; MICROFLUIDICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEOMICS; SYSTEMATIC EVOLUTION OF LIGAND BY EXPONENTIAL AMPLIFICATION;

ANIMALS; APTAMERS, NUCLEOTIDE; CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PROTEIN BINDING; PROTEOMICS; SELEX APTAMER TECHNIQUE;

EID: 84861999853     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2011.11.017     Document Type: Article

References (50)

1. Vinkenborg J.L., et al. Aptamers for allosteric regulation. Nat. Chem. Biol. 2011, 7:519-527.
2. Yang X., et al. Strategies for the discovery of therapeutic aptamers. Expert Opin. Drug Discov. 2011, 6:75-87.
3. Meyer C., et al. Cell-specific aptamers as emerging therapeutics. J. Nucleic Acids 2011, 2011:904750.
4. Yoshida Y., et al. Antibody-specific aptamer-based PCR analysis for sensitive protein detection. Anal. Bioanal. Chem. 2009, 395:1089-1096.
5. Keefe A.D., et al. Aptamers as therapeutics. Nat. Rev. Drug Discov. 2010, 9:537-550.
6. Dausse E., Da Rocha Gomes S., Toulme J.J. Aptamers: a new class of oligonucleotides in the drug discovery pipeline?. Curr. Opin. Pharmacol. 2009, 9:602-607.
7. Kim K.S., et al. The fabrication, characterization and application of aptamer-functionalized Si-nanowire FET biosensors. Nanotechnology 2009, 20:235501.
8. Bugaut A., et al. SELEX and dynamic combinatorial chemistry interplay for the selection of conjugated RNA aptamers. Org. Biomol. Chem. 2006, 4:4082-4088.
9. Kang W.J., et al. Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers. Small 2009, 5:2519-2522.
10. Da Pieve C., et al. Modification of thiol functionalized aptamers by conjugation of synthetic polymers. Bioconjugate Chem. 2010, 21:169-174.
11. Smith J.E., et al. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal. Chem. 2007, 79:3075-3082.
12. Lebars I., et al. NMR structure of a kissing complex formed between the TAR RNA element of HIV-1 and a LNA-modified aptamer. Nucleic Acids Res. 2007, 35:6103-6114.
13. Mallikaratchy P.R., et al. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res. 2011, 39:2458-2469.
14. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
15. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
16. Rimmele M. Nucleic acid aptamers as tools and drugs: recent developments. Chembiochem 2003, 4:963-971.
17. Bock C., et al. Photoaptamer arrays applied to multiplexed proteomic analysis. Proteomics 2004, 4:609-618.
18. Gold L., et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010, 5:e15004.
19. Cai W. Aptamers: versatile agents for biomedical applications. Curr. Med. Chem. 2011, 18:4106.
20. Pestourie C., et al. Aptamers against extracellular targets for in vivo applications. Biochimie 2005, 87:921-930.
21. Famulok M., Mayer G. Intramers and aptamers: applications in protein-function analyses and potential for drug screening. Chembiochem 2005, 6:19-26.
22. Mayer G., Jenne A. Aptamers in research and drug development. BioDrugs 2004, 18:351-359.
23. Ng E.W., et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 5:123-132.
24. Ostroff R.M., et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 2010, 5:e15003.
25. Robertson D.L., Joyce G.F. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 1990, 344:467-468.
26. Cox J.C., Ellington A.D. Automated selection of anti-protein aptamers. Bioorg. Med. Chem. 2001, 9:2525-2531.
27. Zhang H., et al. Automated in vitro selection to obtain functional oligonucleotides. Nucleic Acids Symp. Ser. 2000, 44:219-220.
28. Eulberg D., et al. Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist. Nucleic Acids Res. 2005, 33:e45.
29. Yunusov D., et al. Kinetic capillary electrophoresis-based affinity screening of aptamer clones. Anal. Chim. Acta 2009, 631:102-107.
30. Liang S., Connell G.J. An electrochemiluminescent aptamer switch for a high-throughput assay of an RNA editing reaction. RNA 2009, 15:1929-1938.
31. Chen F., et al. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One 2009, 4:e8142.
32. Bar-Haim S., et al. SeleX-CS: a new consensus scoring algorithm for hit discovery and lead optimization. J. Chem. Inf. Model. 2009, 49:623-633.
33. Yamazaki S., et al. Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem. Biol. 2007, 14:804-812.
34. Ogasawara D., et al. Screening of DNA aptamer against mouse prion protein by competitive selection. Prion 2007, 1:248-254.
35. Konig J., et al. Combining SELEX and the yeast three-hybrid system for in vivo selection and classification of RNA aptamers. RNA 2007, 13:614-622.
36. Zimmermann B., et al. Monitoring genomic sequences during SELEX using high-throughput sequencing: neutral SELEX. PLoS One 2010, 5:e9169.
37. Cho M., et al. Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15373-15378.
38. Taouji S., et al. Current screens based on the AlphaScreen technology for deciphering cell signalling pathways. Curr. Genomics 2009, 10:93-101.
39. Dausse E., et al. HAPIscreen, a method for high-throughput aptamer identification. J. Nanobiotechnol. 2011, 9:25.
40. Li N., et al. Technical and biological issues relevant to cell typing with aptamers. J. Proteome Res. 2009, 8:2438-2448.
41. Zhang Y., et al. Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis 2010, 2:907-918.
42. Zueva E., et al. Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion. Int. J. Cancer 2011, 128:797-804.
43. Sefah K., et al. Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 2010, 5:1169-1185.
44. Mayer G., et al. Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat. Protoc. 2010, 5:1993-2004.
45. Berezovski M., et al. Non-SELEX selection of aptamers. J. Am. Chem. Soc. 2006, 128:1410-1411.
46. Drabovich A.P., et al. Selection of smart aptamers by methods of kinetic capillary electrophoresis. Anal. Chem. 2006, 78:3171-3178.
47. Berezovski M.V., et al. Non-SELEX: selection of aptamers without intermediate amplification of candidate oligonucleotides. Nat. Protoc. 2006, 1:1359-1369.
48. Nitsche A., et al. One-step selection of vaccinia virus-binding DNA aptamers by MonoLEX. BMC Biotechnol. 2007, 7:48.
49. Golden M.C., et al. Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J. Biotechnol. 2000, 81:167-178.
50. Turner D.J., et al. Toward clinical proteomics on a next-generation sequencing platform. Anal. Chem. 2011, 83:666-670.